



RIANA Therapeutics enters into collaboration agreement with LDC

Vienna, Austria, and Dortmund, Germany - September 12th, 2023. RIANA Therapeutics, a spin-off from Vetmeduni Vienna has entered into a collaborative agreement with the Lead Discovery Center GmbH, a renowned organization specialized in translational drug discovery. This partnership marks the first important milestone on RIANA Therapeutics' mission to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).

Inhibition of PPIs is an emerging drug modality and a highly promising therapeutic approach for numerous diseases, including cancer, to overcome widespread resistance to drugs already in use and to improve treatment efficacy. Under the now-signed collaboration agreement, LDC will conduct high-throughput screening (HTS) using a diverse compound library of more than 200,000 chemical substances to identify novel PPI inhibitors targeting STAT5, a critical mediator driving the development of Acute Myeloid Leukemia (AML).

Through the strategic partnership with LDC, RIANA Therapeutics secures invaluable access to LDC's profound expertise in the field of early drug discovery. By combining their respective strengths, RIANA Therapeutics and LDC aim to accelerate the translation of innovative discoveries into potential therapeutics, with the declared long-term goal of improving the well-being of patients on a global scale.

Anna Orlova, co-founder and CEO of RIANA Therapeutics, expressed her excitement about the collaboration: "We are thrilled to partner with LDC, a highly experienced player in drug discovery. Their expertise and capabilities will be instrumental in our efforts to develop breakthrough therapeutics for hematopoietic and other cancer types. This collaboration marks a significant milestone for RIANA Therapeutics, and we look forward to working together to advance our shared mission of improving human health."

Peter Nussbaumer, Managing Director at LDC, added: "We are highly motivated to start the challenging discovery of inhibitors targeting oncogenic PPI interactions within this new partnership with RIANA. This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients."

###

About LDC

Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.

LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qorient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.

Further information at www.lead-discovery.de

About RIANA

RIANA Therapeutics was founded in February 2023 as a spin-off of Vetmeduni in Vienna by Anna Orlova, Richard Moriggl, and Oliver Szolar. The technological foundation is based on a proprietary platform technology for the discovery of compounds that target cancer-promoting protein-protein interactions (PPI), enabling a reliable search for inhibitors that block the formation of specific oncogenic PPIs. Building upon this novel proprietary technology, the team led by Orlova is working on developing new compounds specifically targeting AML, as well as other blood cancers and certain types of solid tumors.



Further information at www.rianatx.com

###

>> Contact
PR Lead Discovery Center
+49 (0)231-97 42 70 00
pr@lead-discovery.de

###